The impact of different administration routes of hormonal contraceptives on androgen secretion, glucose metabolism and inflammation. A prospective randomized trial.

The investigators assume, that transdermal or transvaginal hormonal contraception would have less effects on androgen levels, glucose metabolism and inflammatory markers than oral contraceptives.

45 patients are recruited in the study. Each study group will consist of 15 women (aged 20-35 years) receiving oral, transdermal or transvaginal hormonal contraception continuously for 9 weeks. The subjects should have at least 2 months wash out period from all hormonal medication prior to the study.

The measurements for serum sampling and OGTT will be performed before and after 9 weeks of medication.

Inclusion Criteria:

• healthy women aged from 20 to 35 years
• regular menstruation
• no use of hormonal contraception or two months wash-out period
• no contraindications for using hormonal contraception

Exclusion Criteria:

• irregular menstruation
• smoking
• alcohol addiction
• pregnancy or nursing
• hypersensitivity to any components of the products
• headaches with focal neurological symptoms
• serious or multiple risk factors for artery disease
• undiagnosed abnormal genital bleeding
• impaired glucose tolerance or DM-T2